🏛️ Verified NIH Record • Updated 2026-03-24
Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer (NCT03784755)
A Randomized Phase III Trial of Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer [PLATON]
🔵 Active, Not Recruiting Observational / Diagnostic 📋 Clinical Research Protocol Sponsor: Canadian Cancer Trials Group
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to compare the effects of ablative therapy (radiation or surgery) to all sites of disease combined with standard treatments on prostate cancer, compared to the standard or usual treatments used to treat this disease.
Who can join: Review the eligibility criteria below.
Location: BCCA - Victoria — Victoria, British Columbia
Age range: 18 Years
🧪 Interventions in This Study
- Ablative Radiation Therapy (RADIATION)
- Standard of care (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (18 Sites)
- BCCA - Victoria — Victoria, British Columbia
- CancerCare Manitoba — Winnipeg, Manitoba
- QEII Health Sciences Centre — Halifax, Nova Scotia
- Royal Victoria Regional Health Centre — Barrie, Ontario
- Health Sciences North — Greater Sudbury, Ontario
- Juravinski Cancer Centre at Hamilton Health Sciences — Hamilton, Ontario
- Kingston Health Sciences Centre — Kingston, Ontario
- Trillium Health Partners - Credit Valley Hospital — Mississauga, Ontario
- Ottawa Hospital Research Institute — Ottawa, Ontario
- Algoma District Cancer Program — Sault Ste. Marie, Ontario
- Odette Cancer Centre — Toronto, Ontario
- University Health Network — Toronto, Ontario
- CIUSSS de l'Est-de-I'lle-de-Montreal — Montreal, Quebec
- CHUM-Centre Hospitalier de l'Universite de Montreal — Montreal, Quebec
- The Jewish General Hospital — Montreal, Quebec
- Hotel-Dieu de Quebec — Québec, Quebec
- Allan Blair Cancer Centre — Regina, Saskatchewan
- Saskatoon Cancer Centre — Saskatoon, Saskatchewan
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Prostate Cancer Metastatic
- REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer — New York, New York
- Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer — Duarte, California
- Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer — Baltimore, Maryland
- A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer — Duarte, California
- Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) — Orange, California
Explore by condition: All Prostate Cancer Metastatic clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.